<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>Insuasti-Beltran G, Steidler N L, Kang H &amp; Reichard K K (2012) Histopathology CD34+ megakaryocytes (≥30%) are associated with <z:e sem="disease" ids="C0002888" disease_type="Disease or Syndrome" abbrv="">megaloblastic</z:e> <z:hpo ids='HP_0001903'>anaemia</z:hpo> and non-<z:hpo ids='HP_0011009'>acute</z:hpo> myeloid <z:hpo ids='HP_0002664'>neoplasia</z:hpo> Aims:  To evaluate the sensitivity and specificity of CD34 staining of megakaryocytes (MKs), in order to distinguish non-neoplastic and neoplastic bone marrows (BMs) </plain></SENT>
<SENT sid="1" pm="."><plain>Methods and results:  Three hundred BMs (120 non-neoplastic and 180 neoplastic) were evaluated for percentage and intensity of CD34 staining of MKs </plain></SENT>
<SENT sid="2" pm="."><plain>The selected non-neoplastic cases included <z:hpo ids='HP_0001903'>anaemia</z:hpo>, autoimmune conditions, <z:hpo ids='HP_0001973'>immune thrombocytopenia</z:hpo> (<z:chebi fb="0" ids="16039">ITP</z:chebi>), and staging BMs </plain></SENT>
<SENT sid="3" pm="."><plain>The neoplastic cases included <z:hpo ids='HP_0002863'>myelodysplastic syndromes</z:hpo> and/or myeloproliferative <z:hpo ids='HP_0002664'>neoplasms</z:hpo> (<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MDS</z:e>, MPN, <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MDS</z:e>/MPN) </plain></SENT>
<SENT sid="4" pm="."><plain>Eight per cent of non-neoplastic (9/120) cases and 13% of neoplastic (24/180) cases showed ≥30% CD34+ MKs, and these were essentially restricted to cases of <z:e sem="disease" ids="C0002888" disease_type="Disease or Syndrome" abbrv="">megaloblastic</z:e> <z:hpo ids='HP_0001903'>anaemia</z:hpo> (MBA) and non-<z:hpo ids='HP_0011009'>acute</z:hpo> myeloid <z:hpo ids='HP_0002664'>neoplasms</z:hpo> </plain></SENT>
<SENT sid="5" pm="."><plain>The finding of ≥30% CD34+ MKs did not distinguish between categories of non-<z:hpo ids='HP_0011009'>acute</z:hpo> myeloid <z:hpo ids='HP_0002664'>neoplasms</z:hpo> </plain></SENT>
<SENT sid="6" pm="."><plain><z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MDS</z:e> cases with ≥30% CD34+ MKs had lower platelet counts than cases with &lt;30% (P = 0.03) </plain></SENT>
<SENT sid="7" pm="."><plain>Conclusions:  In complex BM cases, the presence of ≥30% CD34+ MKs constitutes a potentially useful diagnostic tool with which to distinguish non-<z:hpo ids='HP_0011009'>acute</z:hpo> myeloid <z:hpo ids='HP_0002664'>neoplasms</z:hpo> and MBA from non-MBA reactive conditions, for minimal additional cost </plain></SENT>
</text></document>